# Systematic Screening for Deep Vein Thrombosis in Critically Ill Inpatients With COVID-19: Impact on the Incidence of Venous Thromboembolism

François-Xavier Lapébie, Vincent Minville, Agnès Ribes, Bertrand Combis, Arthur Thery, Thomas Geeraerts, Stein Silva, Alessandra Bura-Rivière, Fanny Vardon-Bounes

► To cite this version:

François-Xavier Lapébie, Vincent Minville, Agnès Ribes, Bertrand Combis, Arthur Thery, et al. Systematic Screening for Deep Vein Thrombosis in Critically Ill Inpatients With COVID-19: Impact on the Incidence of Venous Thromboembolism. Frontiers in Medicine, 2021, 7, pp.624808. 10.3389/fmed.2020.624808. [hal-04501651]

HAL Id: hal-04501651

https://ut3-toulouseinp.hal.science/hal-04501651v1

Submitted on 12 Mar 2024

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>

Distributed under a Creative Commons CC BY 4.0 - Attribution - International License
<figure><img src="image_2.png" /></figure>

Check for
updates

# Systematic Screening for Deep Vein Thrombosis in Critically Ill Inpatients With COVID-19: Impact on the Incidence of Venous Thromboembolism

François-Xavier Lapébie<sup>1,2*</sup>, Vincent Minville<sup>3,4</sup>, Agnès Ribes<sup>4,5</sup>, Bertrand Combis<sup>3</sup>, Arthur Thery<sup>1</sup>, Thomas Geeraerts<sup>3,6</sup>, Stein Silva<sup>3,6</sup>, Alessandra Bura-Rivière<sup>1,7</sup> and Fanny Vardon-Bounes<sup>3,4</sup>

**OPEN ACCESS**

**Edited by:**
Eleni Gavriliaki,
G. Papanikolaou General
Hospital, Greece

**Reviewed by:**
Gianluca Di Micco,
Ospedale Buon Consiglio
Fatebenefratelli, Italy
Bipin P. Kulkarni,
National Institute of
Immunohaematology (ICMR), India

**\*Correspondence:**
François-Xavier Lapébie
lapebie.fx@chu-toulouse.fr;
fx.lapebie@gmail.com

**Specialty section:**
This article was submitted to
Hematology,
a section of the journal
Frontiers in Medicine

**Received:** 01 November 2020
**Accepted:** 03 December 2020
**Published:** 14 January 2021

**Citation:**
Lapébie F-X, Minville V, Ribes A, Combis B, Thery A, Geeraerts T, Silva S, Bura-Rivière A and Vardon-Bounes F (2021) Systematic Screening for Deep Vein Thrombosis in Critically Ill Inpatients With COVID-19: Impact on the Incidence of Venous Thromboembolism. *Front. Med.* 7:624808.
doi: 10.3389/fmed.2020.624808

**Background:** Several studies suggest an increased incidence of thrombosis in COVID-19 patients. However, evidence on how to prevent and even treat it is scarce. The aim of this study was to compare the cumulative incidence of venous thromboembolism (VTE) of two different methods for lower extremity deep vein thrombosis (LE-DVT) diagnosis: systematic vs. clinically guided complete compression venous ultrasonography (CCUS). We conducted a monocentric, prospective, open-label, non-randomized study. All consecutive patients admitted in three intensive care units (ICUs) of University Hospital of Toulouse for COVID-19 pneumonia were included: one performed systematic screening for LE-DVT, the others did not. The primary outcome was the 21-day cumulative incidence of VTE. The secondary end points were the 21-day cumulative incidences of major bleeding and death.

**Results:** Among the 78 patients included, 27 (34.6%) underwent systematic screening for DVT 7 ± 2 days after ICU admission. Thirty-two patients (41.0%) were diagnosed with VTE, with a 21-day cumulative incidence of 42.3% (95% CI, 31.4–55.2), without difference between screened and non-screened patients (hazard ratio 1.45, 95% CI, 0.72–2.93). In the screened group, the frequency of isolated DVT was higher (25.9 vs. 5.9%, *p*-value = 0.027), but the frequency of pulmonary embolism was not reduced (25.9 vs. 29.4%, *p*-value = 0.745). The 21-day cumulative incidences of major bleeding and death were 9.6% (95% CI, 4.7–19.2) and 10.3% (95% CI, 5.0–20.8), respectively, without difference between the two groups.

**Conclusions:** A systematic screening for DVT in patients hospitalized in ICU was not associated with a higher diagnosis of VTE or a reduced diagnosis of PE.

**Keywords:** COVID-19, venous thromboembolism, ultrasonography, deep vein thrombosis, intensive care unit

<footnote n="1"><sup>1</sup> Department of Vascular Medicine, Toulouse University Hospital, Toulouse, France, <sup>2</sup> UMR 1027 INSERM, Toulouse III - Paul Sabatier University, Toulouse, France, <sup>3</sup> Department of Anesthesiology and Critical Care, Toulouse University Hospital, Toulouse, France, <sup>4</sup> UMR 1048 INSERM, I2MC, Toulouse III - Paul Sabatier University, Toulouse, France, <sup>5</sup> Laboratory of Hematology, Toulouse University Hospital, Toulouse, France, <sup>6</sup> ToNIC (Toulouse Neuro-Imaging Center) INSERM, Toulouse III - Paul Sabatier University, Toulouse, France, <sup>7</sup> UMR 1031 INSERM, StromaLab, Toulouse III - Paul Sabatier University, Toulouse, France</footnote>
# INTRODUCTION

Critically ill patients are at high risk for developing venous thromboembolism (VTE), with a frequency ranging from 5.1 to 15.5% despite the use of low-molecular-weight heparin (LMWH) thromboprophylaxis (1). Incidence is particularly high in patients diagnosed with sepsis, with a 30-day cumulative incidence of VTE of 12.5%, and 31% in patients with acute respiratory distress syndrome (ARDS) (2).

Early data suggested increased incidence of thrombosis in COVID-19 patients, particularly in critically ill patients, and have been confirmed since. In a multicentric study of 184 patients hospitalized in intensive care unit (ICU) with COVID-19 pneumonia, the adjusted cumulative incidence of thrombotic complication was 49% [95% confidence interval (95% CI), 41–57], with a majority of pulmonary embolism (PE) (3). In another monocentric study of 107 ICU patients with COVID-19, the cumulative incidence of PE at 15 days of admission was 20.4% (95% CI, 13.1–28.7), and frequency of PE was twice as high as that of influenza ICU patients admitted the year before (4). In a propensity score matching analysis, COVID-19 patients with ARDS developed more PE than non-COVID-19 patients with ARDS, odds ratio (OR) 6.2 (95% CI, 1.6–23.4) (5).

In a systematic overview of 80 consecutive autopsies of the COVID-19 deaths, 17 PE (21%) were found, of whom eight were fatal. In each of these deaths as well as in 15 others (32 cases, 40%), lower extremities deep vein thrombosis (LE-DVT) were found. The most frequent cause of death was pneumonia, followed by PE combined with pneumonia (6).

The clinical history and physical examination are of poor utility in determining the probability and risk of deep vein thrombosis (DVT) in the ICU (7, 8). An ultrasound-based DVT screening may be helpful to identify early LE-DVT and therefore adapt treatment in order to prevent progression to PE.

# METHOD

## Aim of the Study

The aim of the study was to determine the impact of routine screening for DVT on the number of cumulative VTE at day 21 on patients admitted in ICU for COVID-19 pneumonia. The secondary end points were the cumulative incidences of major bleeding and death at day 21.

## Study Design and Ethics

This prospective, monocentric, cohort study (ECHO-VID) was conducted in Toulouse University Hospital from March 10,

2020, to May 7, 2020. The management of the patients was not modified during the study, since in the site performing systematic screening for LE-DVT, the ultrasound screening is easily accessible and done, while in the other two centers, it is not. Patients were informed that their data would be used for the study. The local ethic committee gave its consent to the collection of the data and the study is declared in the register of observational studies of Toulouse University Hospital (number's register: 2020-091).

## Patients

Consecutive patients admitted in three medico-surgical ICUs for COVID-19 ARDS were identified. SARS-CoV-2 pneumonia was confirmed by a reverse transcription polymerase chain reaction (RT-PCR) test on a nose/throat swab or sputum sample positive for SARS-CoV-2, or, in patients with a negative RT-PCR but with symptoms consistent with COVID-19, by abnormalities highly suspicious of COVID-19 on a chest computed tomography (CT) scan in the absence of an alternative diagnosis. Patients were excluded if their length of ICU stay was <72 h or if acute VTE was already present at ICU admission.

## Procedures

The three ICUs follow the same standardized procedures and clinical protocols. Thrombosis prophylaxis was systematically given in COVID-19 patients without major risk of bleeding. Of the three ICUs, one benefitted from the passage of vascular physicians for systematic bedside lower extremities complete compression venous ultrasonography (LE-CCUS screened group) at day 7 ± 2. The other units did not perform systematic screening (non-screened group). All the centers performed CCUS in cases of suspected DVT (localized tenderness, pitting oedema or swelling in each lower extremity, and central venous catheter dysfunction). Proximal DVT was defined as the thrombus involving at least the popliteal vein and above, and distal DVT was defined as the thrombus involving veins below the popliteal level. Isolated DVT was defined as DVT without associated PE. CT pulmonary angiography (CTPA) was performed only for patients with clinical suspected PE (acute degradation of hemodynamic or respiratory status, difficulties to discontinue mechanical ventilation). The three ICUs strictly applied the same thromboprophylaxis protocol: until April 3, a standard dose anticoagulant thromboprophylaxis with enoxaparin 4,000 IU once-daily or 4,000 IU twice-daily for patients with a body mass index >40 kg/m². From April 3 onwards, patients received an intermediate-dose anticoagulant thromboprophylaxis with enoxaparin 80 IU/kg per day, in one injection for patients with a body weight of ≤100 kg and in two injections for patients with a body weight of >100 kg. In case of severe renal impairment, patients received subcutaneous UFH 5,000 IU two or three times a day without anti-factor Xa monitoring. Patients with acute PE or DVT were treated with therapeutic anticoagulation by intravenous UFH or LMWH (enoxaparin 100 IU/kg twice daily or tinzaparin 175 IU/kg once daily). Patients with indication for oral therapeutic anticoagulation before hospital admission like atrial fibrillation, history of VTE, or mechanical heart valves were switched

<footnote>**Abbreviations:** 95% CI, 95% confidence interval; ARDS, Acute respiratory distress syndrome; CCUS, Complete compression venous ultrasonography; COPD, Chronic obstructive pulmonary disease; CTPA, Computed tomography-pulmonary angiography; CT scan, Computed tomography scan; DVT, Deep vein thrombosis; ECMO, Extracorporeal membrane oxygenation; eGFR, Estimated glomerular filtration rate; HR, Hazard ratio; ICU, Intensive care unit; ISTH, International Society of Thrombosis and Haemostasis; LE-DVT, Lower extremity deep vein thrombosis; LMWH, Low-molecular-weight heparin; PE, Pulmonary embolism; RT-PCR, Reverse transcription polymerase chain reaction; SD, Standard deviation; UE-DVT, Upper extremity deep vein thrombosis; UFH, Unfractionated heparin; VTE, Venous thromboembolism.</footnote>
to enoxaparin 100 IU/kg twice daily, reduced to 100 IU/kg once daily if estimated glomerular filtration rate (eGFR) is between 15 and 29 ml/min/1.73 m², or intravenous UFH with a goal of 0.3–0.6 IU/ml of antifactor Xa activity if GFR ≤ 14 ml/min/1.73 m².

## End Points

The primary outcome was the cumulative incidence of objectively confirmed VTE (symptomatic or not), including PE, LE-DVT, and catheter-associated upper extremity (UE)-DVT, during 21 days in the hospital. The secondary outcomes were the cumulative incidences of major bleeding [International Society of Thrombosis and Haemostasis (ISTH)-defined] and death, during the first 21 days following ICU admission (9). We did not adjudicate deaths to identify fatal PE, as all but one death was due to hypoxemic respiratory failure that can be indistinguishable from fatal PE.

## Statistical Analysis

Categorical variables are presented as numbers and percentages. Continuous variables are presented as means and standard deviations (SD). Comparisons were made using $\chi^2$ test for categorical variables or Fisher exact test when appropriate, while Student t-test and Mann-Whitney test were used for continuous variables. The Kaplan-Meier method was used to estimate cumulative incidence of events, with 95% CI. The association between routine screening using LE-CCUS and VTE diagnosis, major bleeding, and death was analyzed by unadjusted Cox proportional-hazard models, after checking for the proportional-hazard assumption. A $p$-value <0.05 was considered to be statistically significant. Analyses were performed on STATA Statistical software (release 14.2, StataCorp LLC®).

## RESULTS

Between March 10 and May 7, 2020, 85 patients were eligible for the study. One patient was excluded due to PE prior to ICU admission, and six patients were excluded because of ICU length of stay <72 h; one of them required extracorporeal membrane oxygenation (ECMO) and underwent a fatal intracranial bleeding 24 h after VTE diagnosis. Finally, 78 patients were included in the analysis. Twenty-seven (34.6%) received systematic screening for DVT by bedside LE-CCUS $7 \pm 2$ days after ICU admission. The clinical and biological characteristics of the population are presented in Table 1. Fifty-five patients underwent CTPA: 22 (81.5%) of the LE-CCUS screened group and 33 (64.7%) of the non-screened group, $p$-value = 0.122.

There were no difference concerning past medical history between the two groups, except for history of transplantation being more frequent in the LE-CCUS screened group (14.8 vs. 2%, $p$-value = 0.046). Of the total population, six patients (7.7%) had a history of VTE, five (6.4%) had atrial fibrillation, two (2.6%) had chronic heart failure, nine (11.5%) suffered from chronic obstructive pulmonary disease (COPD), and six (7.7%) suffered from active neoplasia. Nine (11.5%) were current smokers, 18 (23.1%) had diabetes mellitus, 41 (53.6%) had hypertension, and

17 (21.8%) had dyslipidemia. There was no difference between the two groups regarding ICU organ support therapy, but therapeutic anticoagulation started at ICU admission was more frequent in the LE-CCUS screened group.

During a mean follow-up of 31 $\pm$ 20 days, 32 patients (41.0%) were diagnosed with VTE, with a 21-day cumulative incidence of 42.3% (95% CI, 31.4–55.2). There was no difference in VTE cumulative incidence between LE-CCUS screened and non-screened groups (Figure 1, Table 2). Of note, CCUS was performed in six patients (11.8%) in the non-screened group because of suspected DVT. The type of VTE was PE with or without DVT in 22 patients (28.2%), of whom three were subsegmental PE, proximal LE-DVT in one patient (1.3%), isolated distal LE-DVT in six patients (7.7%), catheter-associated UE-DVT in two patients (2.6%), and catheter-associated UE-DVT + distal LE-DVT in 1 patient (1.3%) (Table 3). All but one VTE were diagnosed in patients receiving prophylactic or therapeutic anticoagulation. In the LE-CCUS screened group, the frequency of PE was not reduced (25.9 vs. 29.4%, $p$-value = 0.745), but the frequency of isolated DVT was higher (25.9 vs. 5.9%, $p$-value = 0.027); however, it was mainly isolated distal LE-DVT. After VTE diagnosis, all but one patient received therapeutic anticoagulation, by LMWH or UFH.

There was no difference in the cumulative incidence of major bleeding and death between LE-CCUS screened and non-screened groups (Table 2). All but one major bleeding were diagnosed in patients receiving therapeutic or prophylactic anticoagulation, with five ear-nose-throat bleeding, four gastrointestinal bleeding, and two retroperitoneal bleeding. The cause of death was refractory hypoxemia in seven patients (9.0%) and fatal intracranial bleeding in one patient (1.3%) treated by therapeutic dose of UFH for PE.

No statistically significant difference between intermediate-dose and standard dose anticoagulant thromboprophylaxis with enoxaparin was observed for VTE, major bleeding, and death, respective unadjusted HR 0.85 (95% CI, 0.34–2.11), $p$-value = 0.731; 0.66 (95% CI, 0.14–3.09), $p$-value = 0.594; and 0.52 (95% CI, 0.06–4.40), $p$-value = 0.551.

## DISCUSSION

Our study confirms the high cumulative incidence of VTE in critically ill patients with COVID-19 pneumonia (42.3%, 95% CI, 31.4–55.2) despite a prophylactic anticoagulation. Previous studies reported that VTE frequency ranged from 6.6 to 37.0% in comparable critically ill patients, despite thromboprophylaxis and without VTE screening, with a 15-day cumulative incidence that ranged from 20.4 to 27% (3, 4, 10–13). The diagnosis was often made within the first week after ICU admission, with a median time from ICU admission of 6 days in the study of Poissy et al. and a median time from hospital admission of 24 h in the study of Lodigiani et al. (4, 12). Frequency of VTE is higher in case of LE-DVT screening by CCUS in ICU, up to 69%, with DVT ranging from 14.7 to 85.4% but mainly distal (14–17). In the only other study evaluating bilateral leg ultrasound screening, the
<table><caption>TABLE 1 | Characteristics of patients in ICU according to systematic screening or not for LE-DVT.</caption><thead><tr><th></th><th>All patients<br>[n = 78 (%)]</th><th>LE-CCUS screened group<br>[n = 27 (%)]</th><th>Non-screened group<br>[n = 51 (%)]</th><th>p-value</th></tr></thead><tbody><tr><td><strong>Demographic data</strong></td><td></td><td></td><td></td><td></td></tr><tr><td>Male sex</td><td>67/78 (85.9)</td><td>24/27 (88.9)</td><td>43/51 (84.3)</td><td>0.739</td></tr><tr><td>Age (years)</td><td>63.3 ± 13.9</td><td>61.5 ± 12.4</td><td>64.2 ± 14.6</td><td>0.411</td></tr><tr><td>BMI (kg/m²)</td><td>27.7 ± 4.4</td><td>28.8 ± 4.0</td><td>27.1 ± 4.5</td><td>0.107</td></tr><tr><td>Days between hospitalization and ICU admission</td><td>1.7 ± 2.2</td><td>2.0 ± 2.3</td><td>1.5 ± 2.2</td><td>0.287</td></tr><tr><td>SOFA score</td><td>5.9 ± 2.2</td><td>6.0 ± 2.4</td><td>5.9 ± 2.1</td><td>0.855</td></tr><tr><td>PaO₂/FiO₂ ratio</td><td>163 ± 62</td><td>167 ± 58</td><td>160 ± 64</td><td>0.617</td></tr><tr><td><strong>Medical history</strong></td><td></td><td></td><td></td><td></td></tr><tr><td>History of VTE</td><td>6/78 (7.7)</td><td>3/27 (11.1)</td><td>3/51 (5.9)</td><td>0.412</td></tr><tr><td>Surgery during the 3 months before</td><td>1/78 (1.3)</td><td>0/27 (0.0)</td><td>1/51 (2.0)</td><td>1.000</td></tr><tr><td>Confined to bed in hospital during the 3 months before</td><td>2/78 (2.6)</td><td>0/27 (0.0)</td><td>2/51 (3.9)</td><td>0.541</td></tr><tr><td>Active cancer</td><td>6/78 (7.7)</td><td>3/27 (11.1)</td><td>3/51 (5.9)</td><td>0.412</td></tr><tr><td><strong>Biologic data at ICU admission</strong></td><td></td><td></td><td></td><td></td></tr><tr><td>eGFR (ml/min/1.73 m²)</td><td>83 ± 27</td><td>82 ± 31</td><td>83 ± 24</td><td>0.811</td></tr><tr><td>Hemoglobin (g/dl)</td><td>13.0 ± 2.0</td><td>12.6 ± 2.0</td><td>13.2 ± 2.0</td><td>0.178</td></tr><tr><td>Leukocytes (G/L)</td><td>7.98 ± 3.44</td><td>8.53 ± 3.26</td><td>7.68 ± 3.53</td><td>0.302</td></tr><tr><td>Platelets (G/L)</td><td>223 ± 98</td><td>229 ± 113</td><td>220 ± 91</td><td>0.703</td></tr><tr><td>D-dimer (mg/L)</td><td>1.78 ± 1.07</td><td>1.88 ± 1.11</td><td>1.69 ± 1.05</td><td>0.606</td></tr><tr><td>Prothrombin (% of activity)</td><td>88 ± 12</td><td>86 ± 12</td><td>89 ± 12</td><td>0.445</td></tr><tr><td>aPTT ratio</td><td>1.15 ± 0.29</td><td>1.22 ± 0.56</td><td>1.13 ± 0.11</td><td>0.176</td></tr><tr><td>Fibrinogen (g/L)</td><td>6.8 ± 1.4</td><td>7.1 ± 2.0</td><td>6.7 ± 1.0</td><td>0.353</td></tr><tr><td>CRP (mg/L)</td><td>137.5 ± 90.0</td><td>149.0 ± 93.4</td><td>131.8 ± 88.8</td><td>0.469</td></tr><tr><td><strong>Characteristics of ICU stay</strong></td><td></td><td></td><td></td><td></td></tr><tr><td>Prophylactic anticoagulation at ICU admission</td><td>69/78 (88.5)</td><td>21/27 (77.8)</td><td>48/51 (94.1)</td><td>0.057</td></tr><tr><td>Therapeutic anticoagulation at ICU admission</td><td>7/78 (9.0)</td><td>5/27 (18.5)</td><td>2/51 (3.9)</td><td>0.045</td></tr><tr><td>Catecholamine support</td><td>56/78 (71.8)</td><td>20/27 (74.1)</td><td>36/51 (70.6)</td><td>0.745</td></tr><tr><td>Mechanical ventilation</td><td>66/78 (84.6)</td><td>25/27 (92.6)</td><td>41/51 (80.4)</td><td>0.200</td></tr><tr><td>RRT</td><td>5/78 (6.4)</td><td>3/27 (11.1)</td><td>2/51 (3.9)</td><td>0.334</td></tr><tr><td>ECMO</td><td>5/78 (6.4)</td><td>3/24 (11.1)</td><td>2/51 (3.9)</td><td>0.334</td></tr><tr><td>ICU length of stay (days)</td><td>21 ± 15</td><td>25 ± 16</td><td>18 ± 15</td><td>0.053</td></tr><tr><td>Hospital length of stay since ICU admission (days)</td><td>31 ± 20</td><td>36 ± 19</td><td>29 ± 20</td><td>0.117</td></tr></tbody></table>

aPPT, activated partial thromboplastin time; BMI, body mass index; CCUS, complete compression venous ultrasonography; CRP, C-reactive protein; DVT, deep vein thrombosis; ECMO, extracorporeal membrane oxygenation; eGFR, estimated glomerular filtration rate; ICU, intensive care unit; LE, lower extremity; PaO₂/FiO₂ ratio, ratio of arterial oxygen partial pressure to fractional inspired oxygen; RRT, renal replacement therapy; SOFA, sequential organ failure assessment. Results are expressed as numbers and percentages [n (%)] or mean ± standard deviation.

21-day cumulative incidences of VTE were 59% (95% CI, 42–72) with a screening approach for LE-DVT and 34% (95% CI, 21–46) when excluding asymptomatic events detected by LE-CCUS (18). Isolated distal DVT are frequent and represent 30–50% of all LE-DVT diagnosed on CCUS series (19–21). Therapeutic anticoagulation is not mandatory if the risk of recurrence is low (22).

To date, routine ultrasound screening for the detection of asymptomatic LE-DVT in COVID-19 patients is not recommended (23, 24). However, to the best of our knowledge, our study is the first to compare LE-CCUS screened and non-screened groups, with no difference found regarding cumulative incidences of VTE, major bleeding, and death. Because the majority of PE originated in the deep venous system of LE, undiagnosed DVT and resultant PE may be an important

contributor to hypoxic pulmonary vasoconstriction that would lead to pulmonary hypertension and right ventricular failure in COVID-19 patients, in addition to worsening of ARDS (25). However, in contrast with the relatively frequent report of PE in hospitalized COVID-19 patients, LE-DVT, especially proximal, might be less common and some authors hypothesize that the observed pulmonary vessel occlusions are caused by local thrombi in pulmonary arteries, as a consequence of vascular damage associated with viral infection and severe inflammation, rather than emboli from peripheral veins. LE-DVT screening to prevent PE in this setting might be ineffective (26, 27).

Our study has some limitations. First, the sample size is relatively small due to low peak of COVID-19 patients in our ICU during the study period. Therefore,
<figure><img src="image_3.png" /><figcaption>**FIGURE 1** | Cumulative incidence of venous thromboembolism according to screening or not for LE-DVT.</figcaption></figure>

<table><caption>**TABLE 2** | Cumulative incidence of events at 21 days according to systematic screening or not for LE-DVT, and comparison by unadjusted Cox models, with non-screened group as reference.</caption><thead><tr><th></th><th>All<br/>[% (95% CI)]</th><th>LE-CCUS screened group<br/>[% (95% CI)]</th><th>Non-screened group<br/>[% (95% CI)]</th><th>Hazard ratio<br/>(95% CI)</th><th>p-value</th></tr></thead><tbody><tr><td>Venous thromboembolism</td><td>42.3 (31.4–55.2)</td><td>49.5 (32.2–69.9)</td><td>38.3 (25.3–55.1)</td><td>1.45 (0.72–2.93)</td><td>0.296</td></tr><tr><td>Major bleeding</td><td>9.6 (4.7–19.2)</td><td>14.8 (5.8–34.8)</td><td>6.9 (2.3–20.0)</td><td>1.05 (0.36–3.09)</td><td>0.924</td></tr><tr><td>Death</td><td>10.3 (5.0–20.8)</td><td>3.7 (0.5–23.5)</td><td>14.0 (6.4–29.2)</td><td>0.26 (0.03–2.10)</td><td>0.206</td></tr></tbody></table>

CCUS, complete compression venous ultrasonography; DVT, deep vein thrombosis; LE, lower extremity.

<table><caption>**TABLE 3** | Clinical outcomes of patients according to systematic screening or not for LE-DVT.</caption><thead><tr><th></th><th>All<br/>[n = 78 (%)]</th><th>LE-CCUS screened group<br/>[n = 27 (%)]</th><th>Non-screened group<br/>[n = 51 (%)]</th><th>p-value</th></tr></thead><tbody><tr><td>Venous thromboembolism</td><td>32/78 (41.0)</td><td>14/27 (51.9)</td><td>18/51 (35.3)</td><td>0.157</td></tr><tr><td>Pulmonary embolism</td><td>22/78 (28.2)</td><td>7/27 (25.9)</td><td>15/51 (29.4)</td><td>0.745</td></tr><tr><td>Associated with LE-DVT</td><td>9/78 (11.5)</td><td>7/27 (25.9)</td><td>2/51 (3.9)</td><td>0.007</td></tr><tr><td>Without LE-DVT</td><td>13/78 (16.7)</td><td>0/27 (0.0)</td><td>13/51 (25.5)</td><td>0.003</td></tr><tr><td>Isolated DVT</td><td>10/78 (12.8)</td><td>7/27 (25.9)</td><td>3/51 (5.9)</td><td>0.027</td></tr><tr><td><strong>Deep vein thrombosis localization</strong></td><td></td><td></td><td></td><td></td></tr><tr><td>Proximal LE-DVT</td><td>3/78 (3.9)</td><td>3/27 (11.1)</td><td>0/51 (0.0)</td><td>0.038</td></tr><tr><td>Isolated distal LE-DVT</td><td>14/78 (18.0)</td><td>11/27 (40.7)</td><td>3/51 (5.9)</td><td>&lt;0.001</td></tr><tr><td>Catheter-related UE-DVT</td><td>3/78 (3.9)</td><td>1/27 (3.7)</td><td>2/51 (3.9)</td><td>1.000</td></tr><tr><td>Major bleeding</td><td>14/78 (18.0)</td><td>6/27 (22.2)</td><td>8/51 (15.7)</td><td>0.541</td></tr><tr><td>Death</td><td>8/78 (10.3)</td><td>1/27 (3.7)</td><td>7/51 (13.7)</td><td>0.250</td></tr></tbody></table>

CCUS, complete compression venous ultrasonography; DVT, deep vein thrombosis; LE, lower extremity; UE, upper extremity. Results are expressed as numbers and percentages [n (%)] or mean ± standard deviation.

this study has not enough power to detect a difference in mortality between groups. Secondly, LE-DVT screening was based on a single LE-CCUS at 7 ± 2 days. In literature,

ultrasound screening protocol vary from one single examination (time from ICU admission not specified) to repeated examinations every 5–7 days (14–16, 18). The
results could have been different with earlier screening or
repeated LE-CCUS.

In conclusion, a systematic approach with screening for DVT at 7 ± 2 days of ICU admission does not appear to be associated with a higher diagnosis of VTE or a lower cumulative incidence of PE. Further studies are needed to evaluate the value of routine screening for DVT in critically ill patients admitted for COVID-19 pneumonia.

DATA AVAILABILITY STATEMENT

The datasets analyzed during the current study are available from
the corresponding author on reasonable request.

ETHICS STATEMENT

The studies involving human participants were reviewed and
approved by Toulouse University Hospital local ethic committee
(number's register: 2020-091). Written informed consent for
participation was not required for this study in accordance with
the national legislation and the institutional requirements.

REFERENCES

1. Ribic C, Lim W, Cook D, Crowther M. Low-molecular-weight heparin thromboprophylaxis in medical-surgical critically ill patients: a systematic review. *J Crit Care*. (2009) 24:197-205. doi: 10.1016/j.jcrc.2008.11.002

2. Hanify JM, Dupree LH, Johnson DW, Ferreira JA. Failure of chemical thromboprophylaxis in critically ill medical and surgical patients with sepsis. *J Crit Care*. (2017) 37:206-10. doi: 10.1016/j.jcrc.2016.10.002

3. Klok FA, Kruip MJHA, Van Der Meer NJM, Arbous MS, Gommers D, Kant KM, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. *Thromb Res*. (2020) 191:148-50. doi: 10.1016/j.thromres.2020.04.041

4. Poissy J, Goutay J, Caplan M, Parmentier E, Duburcq T, Lassalle F, et al. Pulmonary embolism in COVID-19 patients: awareness of an increased prevalence. *Circulation*. (2020) 142:184-6. doi: 10.1161/CIRCULATIONAHA.120.047430

5. Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. *Intens Care Med*. (2020) 46:1089-98. doi: 10.1007/s00134-020-06062-x

6. Edler C, Schröder AS, Aepfelbacher M, Fitzek A, Heinemann A, Heinrich F, et al. Dying with SARS-CoV-2 infection-an autopsy study of the first consecutive 80 cases in hamburg, Germany. *Int J Legal Med*. (2020) 134:1275-84. doi: 10.1007/s00414-020-02317-w

7. Crowther MA, Cook DJ, Griffith LE, Devereaux PJ, Rabbat CC, Clarke FJ, et al. Deep venous thrombosis: clinically silent in the intensive care unit. *J Crit Care*. (2005) 20:334-40. doi: 10.1016/j.jcrc.2005.09.011

8. Zhang C, Zhang Z, Mi J, Wang X, Zou Y, Chen X, et al. The cumulative venous thromboembolism incidence and risk factors in intensive care patients receiving the guideline-recommended thromboprophylaxis. *Medicine*. (2019) 98:e15833. doi: 10.1097/MD.0000000000015833

9. Schulman S, Kearon C. Subcommittee on control of anticoagulation of the scientific and standardization committee of the international society on thrombosis and haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. *J Thromb Haemost*. (2005) 3:692-4. doi: 10.1111/j.1538-7836.2005.01204.x

10. Klok FA, Kruip MJHA, Van Der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. *Thromb Res*. (2020) 191:145-7. doi: 10.1016/j.thromres.2020.04.013

AUTHOR CONTRIBUTIONS

F-XL and FV-B designed the study, performed data collection and analysis, interpreted the data, wrote the manuscript, and gave final approval of the manuscript before submission. VM and AB-R designed the study, interpreted the data, revised the manuscript, and gave final approval of the manuscript before submission. AR interpreted the data, wrote the manuscript, and gave final approval of the manuscript before submission. BC and AT performed data collection, interpreted the data, revised the manuscript, and gave final approval of the manuscript before submission. TG and SS interpreted the data, revised the manuscript, and gave final approval of the manuscript before submission. All authors contributed to the article and approved the submitted version.

ACKNOWLEDGMENTS

We thank the departments of Critical Care and
Vascular Medicine for their help in the management of
COVID-19 patients.

11. Thomas W, Varley J, Johnston A, Symington E, Robinson M, Sheares K, et al. Thrombotic complications of patients admitted to intensive care with COVID-19 at a teaching hospital in the United Kingdom. *Thromb Res*. (2020) 191:76-7. doi: 10.1016/j.thromres.2020.04.028

12. Lodigiani C, Iapichino G, Carenzo L, Cecconi M, Ferrazzi P, Sebastian T, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in milan, Italy. *Thromb Res*. (2020) 191:9-14. doi: 10.1016/j.thromres.2020.04.024

13. Tavazzi G, Civardi L, Caneva L, Mongodi S, Mojoli F. Thrombotic events in SARS-CoV-2 patients: an urgent call for ultrasound screening. *Intens Care Med*. (2020) 46:1121-3. doi: 10.1007/s00134-020-06040-3

14. Llitjos JF, Leclerc M, Chochois C, Monsallier JM, Ramakers M, Auvray M, et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. *J Thromb Haemost*. (2020) 18:1743-6. doi: 10.1111/jth.14869

15. Demelo-Rodriguez P, Cervilla-Muñoz E, Ordieres-Ortega L, Parra-Virto A, Toledano-Macias M, Toledo-Samaniego N, et al. Incidence of asymptomatic deep vein thrombosis in patients with COVID-19 pneumonia and elevated d-dimer levels. *Thromb Res*. (2020) 192:23-6. doi: 10.1016/j.thromres.2020.05.018

16. Baccellieri D, Apruzzi L, Ardita V, Rinaldi E, Bertoglio L, Melissano G, et al. The “venous perspective” in lombardia (italy) during the first weeks of the COVID-19 epidemic. *Phlebology*. (2020) 35:295-6. doi: 10.1177/0268355520925727

17. Ren B, Yan F, Deng Z, Zhang S, Xiao L, Wu M, et al. Extremely high incidence of lower extremity deep venous thrombosis in 48 patients with severe covid-19 in wuhan. *Circulation*. (2020) 142:181-3. doi: 10.1161/CIRCULATIONAHA.120.047407

18. Middeldorp S, Coppens M, Van Haaps TF, Foppen M, Vlaar AP, Müller MCA, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. *J Thromb Haemost*. (2020) 18:1995-2002. doi: 10.1111/jth.14888

19. Righini M. Is it worth diagnosing and treating distal deep vein thrombosis? *No. J Thromb Haemost*. (2007) 5 (Suppl. 1):55-9. doi: 10.1111/j.1538-7836.2007.02468.x

20. Righini M, Paris S, Le Gal G, Laroche JP, Perrier A, Bounameaux H. Clinical relevance of distal deep vein thrombosis. Review of literature data. *Thromb Haemost*. (2006) 95:56-64. doi: 10.1160/TH05-08-0588

21. Galanaud JP, Sevestre-Pietri MA, Bosson JL, Laroche JP, Righini M, Brisot D, et al. Comparative study on risk factors and early outcome of symptomatic
distal versus proximal deep vein thrombosis: results from the OPTIMEV study. *Thromb Haemost.* (2009) 102:493–500. doi: 10.1160/TH09-01-0053

22. Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. *Chest*. (2016) 149:315–52. doi: 10.1016/j.chest.2015.11.026

23. Moores LK, Tritschler T, Brosnahan S, Carrier M, Collen JF, Doerschug K, et al. Prevention, diagnosis, and treatment of VTE in patients with COVID-19: CHEST guideline and expert panel report. *Chest*. (2020) 158:1143–63. doi: 10.1016/j.chest.2020.05.559

24. Spyropoulos AC, Levy JH, Ageno W, Connors JM, Hunt BJ, Iba T, et al. Scientific and standardization committee communication: clinical guidance on the diagnosis, prevention and treatment of venous thromboembolism in hospitalized patients with COVID-19. *J Thromb Haemost.* (2020) 18:1859–65. doi: 10.1111/jth.14929

25. Parry AH, Wani AH. Pulmonary embolism in coronavirus disease-19 (COVID-19) and use of compression ultrasonography in its optimal management. *Thromb Res.* (2020) 192:36. doi: 10.1016/j.thromres.2020.05.022

26. Cattaneo M, Bertinato EM, Birocchi S, Brizio C, Malavolta D, Manzoni M, et al. Pulmonary embolism or pulmonary thrombosis in COVID-19? Is the recommendation to use high-dose heparin for thromboprophylaxis justified? *Thromb Haemost.* (2020) 120:1230–2. doi: 10.1055/s-0040-1712097

27. Deshpande C. Thromboembolic findings in COVID-19 autopsies: pulmonary thrombosis or embolism? *Ann Intern Med.* (2020) 173:394–95. doi: 10.7326/M20-3255

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Lapébie, Minville, Ribes, Combis, Thery, Geeraerts, Silva, Bura-Rivière and Vardon-Bounes. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.